Investigation of Phospholipid Differences in Valproic Acid-Induced Autistic Mouse Model Brain Using Mass Spectrometry Imaging.
Hyun Jun JangKyoung Ja KwonChan Young ShinGa Seul LeeJeong Hee MoonTae Geol LeeSohee YoonPublished in: Metabolites (2023)
Autism is a neurodevelopmental disorder for which the cause and treatment have yet not been determined. The polyunsaturated fatty acid (PUFA) levels change rapidly in the blood or cerebrospinal fluid of autistic children and PUFAs are closely related to autism spectrum disorder (ASD). This finding suggests that changes in lipid metabolism are associated with ASD and result in an altered distribution of phospholipids in cell membranes. To further understand ASD, it is necessary to analyze phospholipids in organs consisting of nerve cells, such as the brain. In this study, we investigated the phospholipid distribution in the brain tissue of valproic acid-induced autistic mice using matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI). Phospholipids including phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine were identified in each brain region and exhibited differences between the ASD and control groups. These phospholipids contain docosahexaenoic acid and arachidonic acid, which are important PUFAs for cell signaling and brain growth. We expect that the differences in phospholipids identified in the brain tissue of the ASD model with MALDI-MSI, in conjunction with conventional biological fluid analysis, will help to better understand changes in lipid metabolism in ASD.
Keyphrases
- autism spectrum disorder
- fatty acid
- mass spectrometry
- resting state
- intellectual disability
- attention deficit hyperactivity disorder
- white matter
- high resolution
- functional connectivity
- mouse model
- cerebral ischemia
- liquid chromatography
- cerebrospinal fluid
- cell therapy
- type diabetes
- single cell
- oxidative stress
- young adults
- cell death
- single molecule
- signaling pathway
- photodynamic therapy
- mesenchymal stem cells
- congenital heart disease
- ms ms
- combination therapy
- metabolic syndrome
- fluorescence imaging
- blood brain barrier